Pirkko Tamsen



  • Performance and results-driven executive in Europe with 30 years of extensive experience impacting corporate performance in the life science sector: from start-ups to big pharma companies to CROs.

Clinical Operations, Program Management, CRO Contracting / Governance, Clinical Trials Management (mainly in Europe), Executive Leadership, Business Development, Entrepreneurship, Collaborations / Strategic Partnerships, and Licensing. Native speaker in Swedish and Finnish; fluent in English.
Consultant/CEO, Arandi Innovation AB, Stockholm, Sweden
Consultancy company supporting life science start-ups in delivering results through research, development, and commercialization strategy, including program and project management.
Head, Uppsala Universitet Innovation, Uppsala University, Uppsala, Sweden
Led a team of 30 professionals engaging in idea and business development, intellectual property rights, alliance management, and strategic international corporate partnerships at the top university’s unit for innovation support and technology transfer. Uppsala University has 40,000 students and 5,000 researchers. Start-ups are funded by investors and Uppsala University Holding, and accelerated at Uppsala Innovation Centre.
Chief Executive Officer, Dilaforette AB (now Modus Therapeutics), Stockholm, Sweden
Led the company and instituted strategic business and product development plans for the programs in sickle cell disease and severe malaria, including big pharma licensing contracts and regulatory meetings with FDA and EMA in USA, India, and Thailand. Secured long-term financing for company and contracted supplier for commercial scale production in Italy. Conducted clinical trials in Asia.
Chief Executive Officer, Novasaid AB and Softcure Pharmaceutical AB, Stockholm, Sweden
Led start-up pharmaceutical companies in discovery stage towards licensing to big pharma. The drugs in development were from Nobel Prize-awarded research on prostaglandins, for diseases associated with inflammation (rheumatoid arthritis and osteoarthritis) and a new generation of drugs for treatment of patients with inflammatory bowel disease.
Senior Vice President, Marketing, Sales, and Business Development, A+ Science AB, Stockholm, Sweden
After successful acquisition of SEDOC Pharmaceutical Medicine AB, drove sales and marketing operations at this full service CRO. Created business strategies, set sales force goals, and secured long-term contracts with pharma companies.
Co-Owner / Board Member / Managing Director, Director of Clinical Operations, SEDOC Pharmaceutical Medicine AB, (successfully sold to A+ Science, a larger CRO), Stockholm, Sweden
Developed this full service, Phases 1-3, Scandinavian CRO, including business operations. Served all sizes / types of pharma, biotech, and medical device clients, from start-ups to international big pharma. Provided overall leadership of many programs through an extensive network of consultants and CROs in Europe and North America.

Subscribe and Follow

Have the latest akta Pharmaceutical Development news delivered right to your inbox. 
And we will never share your information.